Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability

@article{Widmer2008RelationshipOI,
  title={Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability},
  author={Nicolas Widmer and Laurent A Decosterd and Serge Leyvraz and Michel Andr{\'e} Duchosal and Anne Rosselet and Maria Debiec-Rychter and Chantal Csajka and J{\'e}r{\^o}me Biollaz and Thierry Buclin},
  journal={British Journal of Cancer},
  year={2008},
  volume={98},
  pages={1633 - 1640}
}
Imatinib has revolutionised the treatment of chronic myeloid leukaemia (CML) and gastrointestinal stromal tumours (GIST). Using a nonlinear mixed effects population model, individual estimates of pharmacokinetic parameters were derived and used to estimate imatinib exposure (area under the curve, AUC) in 58 patients. Plasma-free concentration was deduced from a model incorporating plasma levels of alpha1-acid glycoprotein. Associations between AUC (or clearance) and response or incidence of… CONTINUE READING